BI 836858

· Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for BI 836858, covering 2020-12-21 to 2025-01-27. Get the full timeline:

Most recent: Clinical Trial Update: BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse [Phase 1]

See pricing